Bone markers in osteoporosis and malignancy.

Allan Lipton, L. Costa, Laurence Demers

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Normal bone turnover is characterized by a balance (coupling) between the formation of new bone by osteoblasts and the resorption of old bone by osteoclasts. This bone remodeling takes place at discrete sites in the skeleton called bone remodeling units. Initially, the cells that line bone are replaced by osteoclasts that bring about resorption of the surface of bone. Next, osteoclasts are replaced by osteoblasts that gradually refill this space. This balance between bone formation and bone resorption is altered in most metabolic bone diseases (uncoupling). Over the past two decades many investigators have attempted to develop both sensitive and specific assays for the noninvasive assessment of bone turnover. Biochemical markers of bone formation include total and bone-specific alkaline phosphatase, serum osteocalcin (bone gla protein), and more recently procollagen I extension peptides. During the extracellular processing of type I collagen, there is a cleavage of the aminoterminal (p-coll-I-N) and carboxyterminal (p-coll-I-C) extension peptides prior to fibril formation. These peptides circulate in blood and could be useful markers of bone formation.

Original languageEnglish (US)
Pages (from-to)11-15
Number of pages5
JournalThe Canadian journal of oncology
Volume5 Suppl 1
StatePublished - Dec 1995

Fingerprint

Bone Remodeling
Osteoporosis
Osteoclasts
Bone Resorption
Osteogenesis
Bone and Bones
Osteocalcin
Osteoblasts
Peptides
Neoplasms
Procollagen
Metabolic Bone Diseases
Collagen Type I
Skeleton
Alkaline Phosphatase
Biomarkers
Research Personnel
Cell Line
Serum

Cite this

Lipton, Allan ; Costa, L. ; Demers, Laurence. / Bone markers in osteoporosis and malignancy. In: The Canadian journal of oncology. 1995 ; Vol. 5 Suppl 1. pp. 11-15.
@article{f80185b4ac084e27a72613a29729a17e,
title = "Bone markers in osteoporosis and malignancy.",
abstract = "Normal bone turnover is characterized by a balance (coupling) between the formation of new bone by osteoblasts and the resorption of old bone by osteoclasts. This bone remodeling takes place at discrete sites in the skeleton called bone remodeling units. Initially, the cells that line bone are replaced by osteoclasts that bring about resorption of the surface of bone. Next, osteoclasts are replaced by osteoblasts that gradually refill this space. This balance between bone formation and bone resorption is altered in most metabolic bone diseases (uncoupling). Over the past two decades many investigators have attempted to develop both sensitive and specific assays for the noninvasive assessment of bone turnover. Biochemical markers of bone formation include total and bone-specific alkaline phosphatase, serum osteocalcin (bone gla protein), and more recently procollagen I extension peptides. During the extracellular processing of type I collagen, there is a cleavage of the aminoterminal (p-coll-I-N) and carboxyterminal (p-coll-I-C) extension peptides prior to fibril formation. These peptides circulate in blood and could be useful markers of bone formation.",
author = "Allan Lipton and L. Costa and Laurence Demers",
year = "1995",
month = "12",
language = "English (US)",
volume = "5 Suppl 1",
pages = "11--15",
journal = "The Canadian journal of oncology",
issn = "1183-2509",

}

Lipton, A, Costa, L & Demers, L 1995, 'Bone markers in osteoporosis and malignancy.', The Canadian journal of oncology, vol. 5 Suppl 1, pp. 11-15.

Bone markers in osteoporosis and malignancy. / Lipton, Allan; Costa, L.; Demers, Laurence.

In: The Canadian journal of oncology, Vol. 5 Suppl 1, 12.1995, p. 11-15.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Bone markers in osteoporosis and malignancy.

AU - Lipton, Allan

AU - Costa, L.

AU - Demers, Laurence

PY - 1995/12

Y1 - 1995/12

N2 - Normal bone turnover is characterized by a balance (coupling) between the formation of new bone by osteoblasts and the resorption of old bone by osteoclasts. This bone remodeling takes place at discrete sites in the skeleton called bone remodeling units. Initially, the cells that line bone are replaced by osteoclasts that bring about resorption of the surface of bone. Next, osteoclasts are replaced by osteoblasts that gradually refill this space. This balance between bone formation and bone resorption is altered in most metabolic bone diseases (uncoupling). Over the past two decades many investigators have attempted to develop both sensitive and specific assays for the noninvasive assessment of bone turnover. Biochemical markers of bone formation include total and bone-specific alkaline phosphatase, serum osteocalcin (bone gla protein), and more recently procollagen I extension peptides. During the extracellular processing of type I collagen, there is a cleavage of the aminoterminal (p-coll-I-N) and carboxyterminal (p-coll-I-C) extension peptides prior to fibril formation. These peptides circulate in blood and could be useful markers of bone formation.

AB - Normal bone turnover is characterized by a balance (coupling) between the formation of new bone by osteoblasts and the resorption of old bone by osteoclasts. This bone remodeling takes place at discrete sites in the skeleton called bone remodeling units. Initially, the cells that line bone are replaced by osteoclasts that bring about resorption of the surface of bone. Next, osteoclasts are replaced by osteoblasts that gradually refill this space. This balance between bone formation and bone resorption is altered in most metabolic bone diseases (uncoupling). Over the past two decades many investigators have attempted to develop both sensitive and specific assays for the noninvasive assessment of bone turnover. Biochemical markers of bone formation include total and bone-specific alkaline phosphatase, serum osteocalcin (bone gla protein), and more recently procollagen I extension peptides. During the extracellular processing of type I collagen, there is a cleavage of the aminoterminal (p-coll-I-N) and carboxyterminal (p-coll-I-C) extension peptides prior to fibril formation. These peptides circulate in blood and could be useful markers of bone formation.

UR - http://www.scopus.com/inward/record.url?scp=0029433640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029433640&partnerID=8YFLogxK

M3 - Article

VL - 5 Suppl 1

SP - 11

EP - 15

JO - The Canadian journal of oncology

JF - The Canadian journal of oncology

SN - 1183-2509

ER -